However, an increasing number of studies have suggested that DM develops as an immune-related adverse event in response to treatment of cancers with immune checkpoint inhibitors (e.g., CTLA-4 inhibitor, ipilimumab) [5]. Here, CTLA4 is linked to dermatomyositis.